logo
logo

Novellus Closes $57M Series C Financing

Sep 21, 2020•almost 5 years ago

Amount Raised

$57 Million

Round Type

series c

Jerusalem

Description

Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today that it has raised $57 million in a Series C financing round. The round was led by Pontifax, and joined by OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One, as well as existing investors.

Company Information

Company

Novellus

Location

Jerusalem, Jerusalem District, Israel

About

Novellus is a clinical-stage drug development company. Novellus focuses on the development of compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Novellus’ leading project, PLX-8394, is in clinical development (NCT02428712).

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech